SCHEMBL4711032

SCHEMBL4711032

CCNCC1CCNCC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GNAI3 P08754 2/20 0.58
GNAO1 P09471 2/20 0.58
GNAI1 P63096 2/20 0.58
SAT1 P21673 1/20 0.48
ALOX15 P16050 2/20 0.46
ANPEP P15144 1/20 0.46
ERAP2 Q6P179 1/20 0.46
TSHR P16473 1/20 0.43
PRMT5 O14744 1/20 0.42
WDR77 Q9BQA1 1/20 0.42
KCNH2 Q12809 1/20 0.40
SLC6A1 P30531 2/20 0.39
GABRA5 P31644 2/20 0.39
GABRB2 P47870 2/20 0.39
SLC6A12 P48065 2/20 0.39
SLC6A11 P48066 2/20 0.39
SLC6A13 Q9NSD5 2/20 0.39
GABRA1 P14867 1/20 0.39
GABRR1 P24046 1/20 0.39
GABRA4 P48169 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2266332 0.86
SCHEMBL23134315 0.86
SCHEMBL10683878 0.86
SCHEMBL21987001 0.85 GNAI3 (0.55) GNAI3GNAO1GNAI1ALOX15ANPEP
Hydrochloric Acid SCHEMBL9437325 0.85 GNAI3 (0.49) GNAI3GNAO1GNAI1SAT1ALOX15
Hydrochloric Acid SCHEMBL7013278 0.85 GNAI3 (0.49) GNAI3GNAO1GNAI1SAT1ALOX15
Hydrochloric Acid SCHEMBL10681624 0.85 GNAI3 (0.49) GNAI3GNAO1GNAI1SAT1ALOX15
Hydrochloric Acid SCHEMBL10681646 0.85 GNAI3 (0.49) GNAI3GNAO1GNAI1SAT1ALOX15
SCHEMBL5645562 0.82 GNAI3 (0.53) GNAI3GNAO1GNAI1SAT1ALOX15
SCHEMBL13772115 0.82 GNAO1 (0.70) GNAI3GNAO1GNAI1SAT1ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230322723-A1 COMPOUNDS FOR SUPPRESSING EGFR MUTANT CANCER AND PHARMACEUTICAL USE THEREOF J2H BIOTECH INC. (KR) 2023-10-12 US disclosed
WO-2023093728-A1 BRM SELECTIVE DEGRADATION AGENT COMPOUND AND USE THEREOF 江苏先声药业有限公司 2023-06-01 WO disclosed
EP-3921319-A1 IMIDAZO [2, 1-F] [1, 2, 4] TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST BeiGene, Ltd. (KY) 2021-12-15 EP disclosed
WO-2021154665-A1 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS BRISTOL-MYERS SQUIBB COMPANY (US) 2021-08-05 WO disclosed
US-20210087184-A1 AMINO-BENZOISOTHIAZOLE AND AMINO-BENZOISOTHIADIAZOLE AMIDE COMPOUNDS ALCON INC. (CH) 2021-03-25 US disclosed
US-20200316089-A1 1,2-DIHYDRO-3H-PYRAZOL-3-ONE COMPOUNDS AND METHODS OF USING SAME Frequency Therapeutics, Inc. 2020-10-08 US disclosed
WO-2020160710-A1 IMIDAZO [2, 1-F] [1, 2, 4] TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST BEIGENE, LTD. (KY) 2020-08-13 WO disclosed
EP-2699546-B1 GAS CAPTURE PROCESS COMMONWEALTH SCIENT & INDUSTRIAL RESEARCH ORGANISATION (AU) 2019-06-26 EP disclosed
US-20170233374-A1 T-TYPE CALCIUM CHANNEL MODULATOR AND USES THEREOF UTI LIMITED PARTNERSHIP (CA) 2017-08-17 US disclosed
US-9718815-B2 Heterocyclic compounds and uses thereof INFINITY PHARMACEUTICALS, INC. (US) 2017-08-01 US disclosed
EP-1948663-A2 PYRAZOLO-PYRIMIDINES AS CASEIN KINASE II (CK2) MODULATORS Exelixis, Inc. (US) 2008-07-30 EP disclosed
EP-1818340-A1 GLYCOPEPTIDE ANTIBIOTIC MONOMER DERIVATIVES National University Corporation Nagoya University (JP) 2007-08-15 EP disclosed
WO-2007082880-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-07-26 WO disclosed
WO-2007082873-A1 HETEROCYCLYLALKYL DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-07-26 WO disclosed
WO-2007048066-A2 PYRAZOLO-PYRIMIDINES AS CASEIN KINASE II (CK2) MODULATORS EXELIXIS, INC. (US) 2007-04-26 WO disclosed
CN-1295563-A 2-arylethyl- (piperidin-4-ylmethyl) amine derivatives as muscarinic receptor antagonists HOFFMANN LA ROCHE (CH) 2001-05-16 CN disclosed
CN-1017800-B TRICYCLIC COMPOUNDS HOFFMANN LA ROCHE (CH) 1992-08-12 CN disclosed
US-4864023-A MICROBIOCIDES, BACTERICIDES HOFFMANN-LA ROCHE INC. (US) 1989-09-05 US disclosed
US-4801584-A ANTIMICROBIAL HOFFMANN-LA ROCHE INC. (US) 1989-01-31 US disclosed
CN-87106838-A Tricyclic compound 1988-05-11 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230322723-A1 COMPOUNDS FOR SUPPRESSING EGFR MUTANT CANCER AND PHARMACEUTICAL USE THEREOF EGFR, KRAS, ERBB2 GNAI3 459/4885GNAO1 2007/4885GNAI1 462/4885
US-20200316089-A1 1,2-DIHYDRO-3H-PYRAZOL-3-ONE COMPOUNDS AND METHODS OF USING SAME DCX, MCL1, MKI67 GNAI3 1537/4885GNAO1 2939/4885GNAI1 1864/4885
US-20170233374-A1 T-TYPE CALCIUM CHANNEL MODULATOR AND USES THEREOF CACNA1E, CACNA1G, TRPC6 GNAI3 833/4885GNAO1 594/4885GNAI1 1083/4885
US-20210087184-A1 AMINO-BENZOISOTHIAZOLE AND AMINO-BENZOISOTHIADIAZOLE AMIDE COMPOUNDS ATM, MAP3K15, MAP3K3 GNAI3 583/4885GNAO1 764/4885GNAI1 548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.